Actinogen Medical Limited · ASX:ACW
Actinogen Medical — BIO Digital 2021
16 slides from Actinogen Medical's conference presentation, Jun 22, 2021
Slide 1: BIO Digital Presentation
BIO Digital Presentation Dr. Steven Gourlay MBBS FRACP PhD MBA: CEO & MD June 2021
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Actinogen Medical Limited. (“Actinogen” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to mak
Slide 3: Actinogen snapshot
Actinogen snapshot Actinogen Medical (ASX:ACW) is a public company developing Xanamem®1; a novel small molecule for cognitive impairment 2014 in-license of Xanamem mid-Phase 1 from University of Edinburgh Founded on Designed to lower intracellular cortisol levels in the brain excellent science
Slide 4: Xanamem – small molecule drug with a novel mechanism of action
Xanamem – small molecule drug with a novel mechanism of action Xanamem is a brain-penetrant 11β-HSD1 small molecule enzyme inhibitor; designed to inhibit excessive cortisol production in the brain 4
Slide 5: Xanamem snapshot
Xanamem snapshot Small molecule, once daily, with safety and rapid onset of cognitive improvement demonstrated in humans Xanamem exhibits High levels of brain target engagement demonstrated favourable Favourable pharmaceutical properties across multiple domains characteristics Low drug interac
Slide 6: Clinical pipeline for Xanamem
Clinical pipeline for Xanamem Major clinical trials to be initiated in CY21 targeting brain penetration, improved cognition and other benefits Planned studies Pathway (illustrative) Outlook Mild cognitive XanaMIA Stage of AD severity for future trials impairment due to Part A: 10mg, 5mg, Placebo inf
Slide 7: Significant cognitive efficacy signal achieved
Significant cognitive efficacy signal achieved Phase 1 randomized, placebo-controlled XanaHES study demonstrated clinically and statistically significant cognitive efficacy signals1 Cognitive Evaluation (Test) p value Treatment Effect Size: Cohen’s d All Male Female Week 2 Week 4 Week 8 Week 12 Work
Slide 8: Timecourse of cognitive improvement in XanaHES
Timecourse of cognitive improvement in XanaHES1 Working memory (One Back Test) Visual attention (Identification Test) Psychomotor function (Detection Test) Strongly statistically Statistically Good trend to significant result significant result a positive result Score Score Score P<0.01 P=0.05 P=0.0
Slide 9: Review of data supports a low Xanamem dose
Review of data supports a low Xanamem dose Human Target Occupancy Study PET data demonstrates consistent suppression of enzyme activity at 5mg Xanamem doses and above BASELINE AFTER DOSE 5mg Xanamem 10mg Xanamem 20mg Xanamem SUVRcarotid PET data demonstrates that Xanamem extensively binds to the 11β
Slide 10: Bridging positive Phase I cognition data to Alzheimer's patients
Bridging positive Phase I cognition data to Alzheimer’s patients XanaMIA XanaMIA XanaMIA Study - Part A - Part B Healthy elderly Mild Cognitive Mild Impairment Clinical AD Moderate Severe due to Alzheimer’s disease Functional Impairment in later Alzheimer’s disease >US$13.7B Target annual peak sales
Slide 11: XanaMIA Phase II trial to commence mid CY21
XanaMIA Phase II trial to commence mid CY21 Targeting the first stage of Alzheimer’s disease XanaMIA - Part A XanaMIA - Part B Healthy older subjects - with normal cognition, Targeting subjects with mild cognitive impairment ≥50 years of age (same as XanaHES trial) due to Alzheimer’s disease (us
Slide 12: Strong Leadership and Management
Strong Leadership and Management Leadership has a strong track record in drug development and extensive commercial experience Experienced Board of Directors.. …with a talented management team in place 30+ years experience in the Dr. Geoff Brooke 30+ years experience in the Dr. Steven Gourlay dev
Slide 13: Global Advisory Boards
Global Advisory Boards World-leading, premier academics in Alzheimer’s Disease1 Xanamem Clinical Advisory Board Scientific Advisory Board Positions Xanamem at the forefront Combining deep understanding of endocrinology, of drug development 11β-HSD1 and drug discovery Prof. Craig Ritchie Prof. Colin
Slide 14: Corporate overview
Corporate overview Recent strong interest in ACW stock Trading Information Share Price Performance2 (YTD) 52 week high A$0.099 Share price (A$) Volume (K) 52 week low A$0.017 0.1 80000 Number of shares 1,660.6M 0.09 70000 Market capitalisation (24 May 2021) A$159.4M 0.08 Net cash1 A$15.2M 60000 0.07
Slide 15: Significant value upside for Actinogen
Significant value upside for Actinogen Accelerate clinical development Potential commercial & corporate value Expand pipeline with additional indications Pharma engagement Actinogen is actively engaging with potential and clinical trials, providing multiple shots on future partners on a regular
Slide 16: Next steps and key catalysts
Next steps and key catalysts Strong balance sheet, good clinical cognitive activity and safety from which to launch multiple Phase II trials Clinical trials to commence in 2021* XanaMIA Part A data expected in H1 2022 XanaFX data expected by early 2023 XanaMIA Part B data expected 2023 Pur